BASHH: HIV papers

Laura Waters Consultant GU/HIV Medicine Mortimer Market Centre, CNWL, London

Content

- 5 in 1
- A new dawn
- Weight
- Lungs
- But first....

What do YOU think?


- What has changed most in your discussions with patients?
- PARTNER-2 trial

Literally the best message ever!



Literally the best message ever!

NEGLIGIBLE IS NOT HELPFUL!



UNDETECTABLE = UNTRANSMITTABLE

ZERO! NO RISK! CANNOT PASS IT ON


TELL ALL PATIENTS & STAFF, AS MANY TIMES AS NECESSARY

Thank you Professor Alison Rodger





Stigma: a cloud over the HIV cascade



90:90:90:90:90:90 DIAGNOSED ON ART VL UD QOL

5 IN 1

5 DRUGS IN 1 SLIDE

Recent/imminent* *according to your country

Good for defined groups Weakness is rilpivirine? Safety & tolerability driven by comparators No first-line data

GEMINI 96W imminent FDC in England not imminent? Caution late presenters Caution renally adjusted 3TC An ideal first-line regimen?

Role in NNRTI resistance? Dual therapy?


Looks good Non-TAF indication in England? Caution resistance data

Presenter's possibly off-licence & arguably not entirely evidence based opinions

A NEW DAWN(ING)

DAWNING: Study Design


Open-label, randomized noninferiority phase IIIb study



^a–12% noninferiority margin. BL, baseline; ITT-E, intent-to-treat–exposed; VL, viral load.


Brown et al. CROI 2019; Seattle, WA. Slides 144. Aboud et al. Lancet Infect Dis. 2019 [Epub ahead of print].

W48 ITT-E by K65R & TAMs




Brown et al. CROI 2019; Seattle, WA. Slides 144.

W48 ITT-E by M184V/I +/- other NRTI RAMs



Brown et al. CROI 2019: Seattle, WA. Slides 144.

Snapshot outcomes overall & M184V/I With XTC population at W48: ITT-E Analysis



^aM184V/I alone or plus additional NRTI mutations. ITT-E, intent to treat–exposed; XTC, 3TC or FTC use.


Brown et al. CROI 2019; Seattle, WA. Slides 144.

Applying DAWNING to practice

- DTG superior to LPV/r second line
 - Can we extrapolate to DRV/r?
- DTG works well with an impaired NRTI backbone
- EACS guidelines for VF with resistance:
 - Any regimen should use at least 1 fully active boosted plus 1 drug from a new class, or 1 NNRTI assessed by genotypic testing.
 - Alternatively, DTG (when fully active) + 2 NRTIs, of which at least 1 NRTI is fully active

WEIGHT

Weight: randomised studies



Waters L et al. P102 Glasgow 2018; Hill A et al, J Virus Erad 2019; Landowitz et al., CROI 2019 abstract 34LB; Hare et al., abstract 104

Weight: cohort data

- Several (not all) studies (switch & 1st line) report greater weight on INSTI vs other classes
- DTG > earlier INSTI
- ABC & TAF > TDF
- Risk factors
 - Female, non-white, >50 years

Why?

- Return to health?
- A new lipohypertrophy?
- 'Obesogenic' environment?
- Fewer GI side effects?
- Are people happier (or sadder) on integrases?
- Backbone? Is TDF protective?
- Something else? DTG & melanocortin....
- Is it clinically important????

Every cloud....

June 14, 2019 EDITORIAL

Could excess body weight be good for cognitive health in chronic HIV infection?

Lucette A. Cysique, 💿 Lambros Messinis, Steven M. Albert

First published June 14, 2019, DOI: https://doi.org/10.1212/WNL.00000000007769

Article Info & Disclosures

Cognitive health in HIV-infected persons continues to be an important area of investigation, especially as the HIV epidemic is aging. Understanding the factors that may contribute to, or guard against, cognitive decline in the aging HIV population is necessary to develop and evaluate treatments that improve outcomes and reduce elderly dementia risk. In this issue of *Neurology*[®], a complex study¹ focusing on men's cognitive health using data from the prospective Multicenter AIDS Cohort Study (MACS) shows established but also unexpected relationships among midlife adiposity, and waist circumference, HIV status, and 10-year trajectory of cognitive performance.

Neurology. 2019 Jun 14.

What can we do?

- Counsel people
- Promote healthy lifestyle (NHS Choices!)
- Record weight & waist circumference
- Collate data



Lung cancer: Kaiser Permanente cohort

Rate ratio (confidence interval) for PLHIV vs HIV-negative PLWHIV = 24,768 (4.9 PYFU); HIV-negative = 257,600 (5.8 PYFU)				<i>P</i> -value <i>trend</i>
Unadjusted		2.0 (1.7-2.2)		<0.001
Adjusted				
Demographics		1.9 (1.5-2.4)		<0.001
+ risk factors		1.4 (1.1-1.7)		0.014
+ prior pneum		1.1 (0.9-1.5)		0.37
Recent CD4 (36 months prior)				
	<200	200-499	>500	
Unadjusted	2.4 (1.2-4.9)	2.3 (1.6-3.4)	1.4 (0.8-2.4)	<0.001
Adjusted				
Demographics	2.2 (1.1-4.5)	1.9 (1.3-2.8)	1.2 (0.7-2.0)	0.008
+ risk factors	1.4 (0.7-2.9)	1.3 (0.9-1.9)	0.9 (0.5-1.5)	0.58
+ prior pneum	1.2 (0.6-2.5)	1.2 (0.8-1.8)	0.8 (0.5-1.4)	0.98

Demographics: age, sex, race/ethnicity, year cohort entry; **Cancer risks**: smoking, drug/alcohol abuse, overweight/obesity Marcus JL et al. AIDS. 2017 Apr 24;31(7):989-993.

Lung cancer screening: US

• USPSTF guidelines:

- Annual low-dose CT (LDCT) for current/former* (quit within 15yrs) smokers aged 55-80 yrs with ≥30 PY history
- Based on NLST trial (n=55,000 PLWH excluded)

• WIHS/MACS analysis (n=12,339; 7,591 with HIV):

- F > M, younger age & shorter smoking history
- USPSTF guidelines would have screened only 25% of cases

*quit less then 15 years prior


Moyer VA et al. Ann Intern Med. 2014;160(5):330-338; Sellers et al, abstract 0015; CROI 2019, Seattle

Lung cancer screening: UK

- UKLS
 - RCT single LDCT vs usual care in high risk (>5% 5-year risk by <u>http://www.MylungRisk.org</u>) 50-75 year olds
 - Lung cancer: 1.7% baseline, 0.4% at 12-month follow-up
 - 86% early stage, 83% resected, £8,466 per QALY gained
- SUMMIT (started December 2018)
 - Largest ever UK trial, 50,000 50-77 year olds (half high risk)
 - Blood marker screening for all, LDCT for high-risk

Take home message

- People with HIV are at higher risk of lung cancer
- Screening thresholds may differ
- Ensure appropriate follow-up of lung nodules
- STOP SMOKING, STOP SMOKING, STOP SMOKING



Summary

- We must talk about U=U uniformly & unambiguously
- New drugs-a-coming (use may be limited in England)
- DAWNING supports use of DTG where previously only PIs dared to treat
- Weight is an emerging issue, aetiology uncertain
- We must all be equipped to discuss smoking cessation

Thank you!

